Core Antigen Expression Is Associated with Hepatic Necroinflammation in \textit{e} Antigen-Negative Chronic Hepatitis B Patients with Low DNA Loads\textsuperscript{v}

Yi-Hsiang Huang,\textsuperscript{1,2,*} Hung-Hsu Hung,\textsuperscript{1†} Che-Chang Chan,\textsuperscript{1,2†} Chi-Jen Chu,\textsuperscript{1} Teh-Ia Huo,\textsuperscript{1,4} Pui-Ching Lee,\textsuperscript{1} Chien-Wei Su,\textsuperscript{1,2} Keng-Hsin Lan,\textsuperscript{1,3} Hui-Chun Huang,\textsuperscript{1} I-Cheng Lee,\textsuperscript{1} Han-Chieh Lin,\textsuperscript{1} and Shou-Dong Lee\textsuperscript{1}

Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan\textsuperscript{1}; Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan\textsuperscript{2}; Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan\textsuperscript{3}; and Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan\textsuperscript{4}

Received 9 November 2009/Returned for modification 16 March 2010/Accepted 20 April 2010

Intrahepatic hepatitis \textit{B} virus (HBV) core antigen (HBcAg) is a hallmark of viral replication in hepatitis \textit{B} virus \textit{e} antigen (HBeAg)-positive chronic hepatitis \textit{B} (CHB). The aim of this study was to evaluate the role of HBcAg in HBeAg-negative CHB. One hundred six HBeAg-negative CHB patients who underwent ultrasonographically guided liver biopsy were reviewed for their HBV DNA load and clinical and histological data. Factors associated with the expression of intrahepatic HBcAg were analyzed. Among the patients, 35 (33\%) were positive for HBcAg by immunohistostaining. In patients whose HBV DNA loads were higher than $10^7$ copies (cp)/ml, nearly one-half (52\%) had detectable HBcAg. Compared with HBcAg-negative patients, HBcAg-positive patients had higher serum alanine transaminase (ALT) and HBV DNA levels and more-severe hepatic necroinflammation. High serum ALT level (>160 U/liter) and HBV viral load were the determinants of HBcAg expression in multivariate analysis. Large amounts of HBcAg expression were frequently detected in patients with high DNA loads, and the patterns of HBcAg distribution were not related to histological activity or HBV DNA levels. In patients with lower HBV DNA loads, the expression of HBcAg was the key factor associated with active hepatic necroinflammation (hazard ratio = 11.25; 95\% confidence interval [CI], 1.42 to 89.26; $P = 0.022$). In conclusion, the expression of HBeAg is not frequent in HBeAg-negative CHB. The expression of intrahepatic HBcAg indicates active hepatic necroinflammation, even in patients with low HBV DNA load. Both HBV viral load and HBcAg expression have implications in the pathogenesis of HBeAg-negative CHB.

Hepatitis \textit{B} virus (HBV) is a circular, partially double-stranded DNA virus (10, 32). HBV infection often leads to chronic hepatitis when it occurs in the neonatal period or early childhood. The natural history of chronic hepatitis \textit{B} (CHB) has been divided into 4 phases: immune tolerance, immune clearance, immune control, and reactivation (7). However, the active phase of HBeAg-negative CHB occurs in some patients (reactivation phase) (13, 15). HBeAg-negative CHB is prevalent in Asia and Mediterranean Europe and may lead to cirrhosis and hepatocellular carcinoma (HCC) (15). Mutations in precore (G1896A) and basic core promoter (A1762T and G1764A) regions that stop or decrease the production of HBeAg are the major variants in HBeAg-negative CHB (2, 22, 27, 31, 33). These mutations theoretically do not interfere with the initiation and production of HBcAg. The intrahepatic HBcAg will reappear in some, but not all, HBeAg-negative CHB cases. The clinical significance of HBcAg in HBeAg-negative CHB is unclear.

Previous reports have found that the localization and expression level of HBcAg are associated with active liver disease or viral replication in the HBeAg-positive stage (7, 14, 26). In the immune tolerance phase, patients usually have a higher level of HBV viremia and the expression of HBcAg is mainly localized in the nucleus, whereas in the immune clearance phase HBcAg can be expressed in the nucleus, cytoplasm, or both in infected hepatocytes (7, 14, 26). It has been suggested that cytoplasmic expression of HBeAg correlates with the severity of liver damage and that nuclear expression of HBcAg reflects the level of viral replication (8). HBcAg distribution might have a certain correlation with serum aminotransferase, HBV DNA, and HBeAg status (18). However, the study population in previous
reports was mainly positive for HBeAg (immune tolerance and immune clearance phases), and only a few patients were in the HBeAg-negative phase. Factors associated with the expression and distribution of intrahepatic HBcAg after HBeAg seroconversion deserve study.

Measurement of HBV DNA levels is now a useful test for evaluating HBV replication and is considered a marker to determine not only the start and the endpoint of antiviral treatment but also the risk of HCC development (23, 28). The clinical significance of reappearance of intrahepatic HBcAg in the reactivation phase of CHB based on HBV viral loads had not been well evaluated. In the current study, we tried to clarify the relationship among the localization, degree of intrahepatic HBcAg expression, level of HBV viremia, and pathological findings in HBeAg-negative CHB.

**MATERIALS AND METHODS**

**Patients.** The chart records of HBeAg-negative CHB patients who underwent liver biopsy from July 2007 to April 2009 at the Division of Gastroenterology, Taipei Veterans General Hospital, were reviewed retrospectively. One hundred six consecutive patients were enrolled; enrollment was limited to patients who (i) were positive for both serum HBV surface antigen (HBsAg) and anti-HBe and negative for HBeAg for more than 6 months, (ii) were positive for quantitative HBV DNA as determined by a Cobas Amplicor HBV Monitor test (Roche Diagnostic Systems, Basel, Switzerland; the detection limit of this assay was 300 copies [cp]/ml), (iii) had had at least two episodes of serum alanine transaminase (ALT) levels ≥80 U/liter (2 times the upper limit of normal [ULN]) 1 month apart prior to liver biopsy, and (iv) were seronegative for autoantibodies (anti-nuclear, anti-smooth muscle, and antimitochondrial antibodies) and antibodies to hepatitis C virus (HCV), hepatitis D virus (HDV), or human immunodeficiency virus (HIV). None of the patients had HCC, and none received antiviral treatments (nucleoside/nucleotide analogues or interferon) before liver biopsy. The HBV DNA levels were obtained within 2 weeks of liver biopsy.
**TABLE 1. Characteristics of 106 HBeAg-negative chronic hepatitis B patients**

| Characteristica | All 106 patients | Patients who were HBeAg: n=71 | Patients who were HBeAg: n=35 | p<0.05 |
|-----------------|-----------------|-------------------------------|-------------------------------|--------|
| Mean age (yr) ± SD | 51.3 ± 12.9 | 50.6 ± 12.9 | 52.7 ± 13.0 | 0.275 |
| Sex (male/female) | 73/33 | 48/23 | 25/10 | 0.86 |
| Median ALT (U/liter) (range) | 123.5 (22–2,390) | 108 (22–2,390) | 167 (43–1,821) | 0.035 |
| Median AST (U/liter) (range) | 77 (19–1,400) | 65 (19–1,400) | 99 (25–1,384) | 0.013 |
| Median total bilirubin (mg/dl) (range) | 0.7 (0.2–10) | 0.64 (0.2–8.8) | 0.79 (0.2–10) | 0.483 |
| Mean PT (INR) ± SD | 1.0 ± 0.8 | 1.0 ± 0.07 | 1.03 ± 0.08 | 0.066 |
| Mean platelets (×10³/mm³) ± SD | 187.3 ± 50.1 | 193.6 ± 50.9 | 174.6 ± 46.4 | 0.034 |
| Median AFP (ng/ml) (range) | 6.07 (1–428) | 5.84 (1–428) | 7.82 (2–114) | 0.076 |
| Mean Ishak fibrosis stage ± SD | 1.94 ± 1.41 | 1.85 ± 1.45 | 2.14 ± 1.33 | 0.149 |
| Mean Ishak necroinflammation grading ± SD | 5.25 ± 3.0 | 4.7 ± 3.02 | 6.34 ± 2.68 | 0.001 |
| No. (%) HBeAg positive | 35 (33.0) | | | |
| Median HBV DNA (log₁₀ cp/ml) (range) | 6.650 (2.4–10.516) | 6.097 (2.4–10.516) | 7.465 (3.358–9.839) | <0.001 |

a PT, prothrombin time; INR, international normalized ratio; AFP, alpha-fetoprotein.
b The chi-square test with Yates’s correction was used for the comparison of sex data, while the Mann-Whitney U test was used for the other variables.

**RESULTS**

**Clinical features of HBeAg-negative CHB cases with intrahepatic HBeAg.** Among the 106 HBeAg-negative CHB patients, 35 (33%) patients were positive for intrahepatic HBeAg (Table 1). Compared with HBeAg-negative patients, HBeAg-positive cases had higher ALT and aspartate aminotransferase (AST) levels, a lower platelet count, a more severe Ishak necroinflammatory grading, and a higher HBV DNA level. There was no statistical difference in sex, age, total bilirubin level, prothrombin time, and Ishak fibrosis stage between patients with and without HBeAg.

**Uni- and multivariate analysis of factors associated with the expression of intrahepatic HBeAg.** In univariate analysis, an ALT of >160 U/liter, an Ishak necroinflammatory grading of ≥7, and an HBV DNA level of >1×10⁶ cp/ml were associated with the expression of intrahepatic HBeAg (Table 2). A serum AST of >80 U/liter also had a trend to associate with HBeAg expression. In multivariate analysis, a serum ALT of >160 U/liter and HBV DNA level higher than 1×10⁶ cp/ml were the factors independently associated with the expression of HBeAg in HBeAg-negative CHB patients (Table 3).

**Distribution patterns of HBeAg and their clinical and pathological features.** Some studies suggested that cytoplasmic HBeAg was a more reliable marker of HBV replication than nuclear core HBeAg (1, 11). Of the 35 intrahepatic-HBeAg-positive patients, 8 (22.9%) had a purely cytoplasmic distribution, 4 (11.4%) had a purely nuclear distribution, 16 (45.7%) had a mixed cytoplasmic and nuclear distribution. There were no significant differences in age, sex, biochemical variables, Ishak fibrosis stage, and necroinflammatory grading among these subgroups of patients (Table 4). Of note, purely cytoplasmic expression of HBeAg had a trend to associate with a lower HBV DNA level (P = 0.061). Cytoplasmic expression of HBeAg did not represent more-severe hepatic necroinflammation.

**Level of HBeAg and its correlation with HBV DNA load and inflammation grading.** The level of intrahepatic HBeAg expression was graded by the pathologist and correlated with the amount of serum HBV DNA load. As shown in Fig. 1B, the

**TABLE 2. Univariate analysis of factors associated with expression of intrahepatic HBeAg**

| Factora | Fraction of patients (%) | p<0.05 |
|---------|-------------------------|--------|
| Age (yr), ≥50 vs >50 | 15/56 (26.8) vs 20/50 (40) | 0.216 |
| Sex, male vs female | 25/73 (34.2) vs 10/33 (30.3) | 0.86 |
| ALT (U/liter), ≥160 vs >160 | 15/63 (23.8) vs 20/43 (46.5) | 0.026 |
| AST (U/liter), ≤80 vs >80 | 13/54 (24.1) vs 22/51 (43.1) | 0.062 |
| Total bilirubin (mg/dl), ≤1.6 vs >1.6 | 32/99 (32.3) vs 2/5 (40) | 0.661 |
| PT (INR), ≤1.1 vs >1.1 | 28/90 (31.1) vs 7/15 (46.7) | 0.375 |
| Platelets, ≤150,000 vs >150,000 | 10/23 (43.5) vs 25/83 (30.1) | 0.34 |
| AFP (ng/ml), ≤20 vs >20 | 26/86 (30.2) vs 6/12 (50) | 0.198 |
| Ishak fibrosis stage, 0-1 vs ≥2 | 13/51 (25.5) vs 22/55 (40) | 0.167 |
| Ishak necroinflammatory grading, <7 vs ≥7 | 20/75 (26.7) vs 15/31 (48.4) | 0.053 |
| HBV DNA (cp/ml), ≤1×10⁶ vs >1×10⁶ | 3/26 (11.5) vs 32/80 (40) | 0.015 |
| HBV DNA (cp/ml), ≤1×10⁶ vs >1×10⁶ | 5/39 (12.8) vs 30/67 (44.8) | 0.002 |

a PT, INR, and AFP are as defined for Table 1.
b Fisher’s exact test was used for total bilirubin and AFP, while the chi-square test with Yates’s correction was used for the other variables.
patients with grade 3/4 expression of HBcAg had the highest HBV DNA viral loads, which are significantly higher than those of patients without HBcAg expression (P < 0.05). A high level of HBcAg expression significantly indicated high HBV viral load.

The degree of HBcAg expression was also compared with the grading of Ishak necroinflammation (Fig. 1B). The data showed that the presence of HBcAg, even at a low level, indicated significant hepatic necroinflammation. Patients with high-level HBcAg expression did not induce more-severe necroinflammation than those with low-level expression.

Correlation of HBV DNA load with the prevalence of HBcAg expression and the severity of necroinflammation. As shown in Fig. 2A, there was a trend to have a higher HBcAg detection rate in patients with a higher HBV DNA load (P = 0.002). The HBcAg expression rate rose from 12% to 52% as the DNA load increased from under 10^5 cp/ml to over 10^7 cp/ml. Noteworthy, higher HBV DNA load was associated with more-severe hepatic necroinflammation grading (Fig. 2B). The median Ishak necroinflammatory gradings were 3.0, 5.0, and 6.0 in patients with HBV DNA loads under 10^5 cp/ml, between 10^5 and 10^6 cp/ml, and over 10^7 cp/ml, respectively (P = 0.015).

Impact of HBV DNA level and HBcAg expression on hepatic necroinflammation. Uni- and multivariate analyses of factors associated with significant hepatic necroinflammation in patients with lower levels of viremia (≤1 × 10^6 cp/ml) revealed that HBcAg expression was the only factor that contributed to active hepatic necroinflammation (Ishak necroinflammatory grading ≥ 7) in HBeAg-negative CHB (Table 5) (hazard ratio = 11.25; 95% confidence interval [CI], 1.42 to 89.26; P = 0.022).

The 26 patients whose HBV DNA levels were lower than 1 × 10^5 cp/ml were analyzed. Among them, four (15.4%) had significant necroinflammation and HBcAg expression was still significantly associated with active hepatic necroinflammation (Fig. 2C).

DISCUSSION

HBcAg is an important viral antigen with regard to induction of the cellular immune response in the course of chronic HBV infection (5). After HBeAg seroconversion, HBcAg is undetectable in anti-HBe-positive HBV remission cases but may reappear in some HBeAg-negative CHB cases (6, 7). A great diversity in the prevalence of intraplatelet HBcAg in HBeAg-negative CHB was reported. A previous study suggested that a high proportion of anti-HBe-positive cases with chronic active hepatitis had detectable nuclear HBcAg, which was considered to be related to viral replication (12). A subsequent study showed that 46% of the anti-HBe-positive chronic active hepatitis cases had intraplatelet HBcAg expression (6), and cytoplasmic expression was found in all the cases. A recent study to evaluate the role of HBcAg in response to antiviral treatment showed that 36% of the CHB cases had intraplatelet HBcAg (34). In the current study, we found that 33% of the cases had intraplatelet HBcAg expression. In patients with higher HBV viral loads (>10^7 cp/ml), 52% had detectable HBcAg. Compatible with previous studies, HBcAg expression was infrequent in HBeAg-negative CHB.

The expression of HBcAg in hepatocytes can attract HBV-specific T cells and recruit non-virus-specific T cells to induce liver inflammation if the infection cannot be controlled (24). Therefore, high serum ALT levels and liver necroinflammation grading were associated with HBcAg expression. In previous studies, different distribution patterns of HBcAg had different degrees of clinical significance (8, 9). Patients with predominantly nuclear HBcAg had higher levels of viral replication (8), whereas those with predominantly cytoplasmic HBcAg had significantly higher levels of biochemical and histological activities (9). However, some studies suggested that nuclear HBcAg might not be involved in HBV replication (1, 11). In those studies, the majority of the patients had HBeAg-positive CHB. Our data focusing on HBeAg-negative patients showed that nearly two-thirds of cases had the mixed-type HBcAg distribution. There is no predominant type of HBcAg distri-

**TABLE 3.** Multivariate analysis of factors associated with expression of intrahepatic HBcAg

| Variable, value | Hazard ratio (95% CI) | SE | P    |
|-----------------|----------------------|----|------|
| ALT, >160 U/liter | 2.719 (1.119–6.609) | 0.453 | 0.027 |
| HBV DNA, >1 × 10^6 cp/ml | 5.659 (1.926–16.628) | 0.550 | 0.002 |

*The variables, including age, sex, and ALT and HBV DNA levels, were used in the final stepwise logistic model.

**TABLE 4.** Characteristics of patients with different patterns of HBcAg distribution

| Characteristic | Value for patients (n = 35) who were HBcAg positive in: | P  |
|---------------|--------------------------------------------------|----|
|               | Cytoplasm (n = 8) | Nucleus (n = 4) | Mixed (n = 23) |
| Mean age (yr) ± SD | 54.5 ± 7.6 | 55.5 ± 5.2 | 51.7 ± 15.4 | 0.686 |
| Median ALT (U/liter) (range) | 228 (79–852) | 178 (138–569) | 116 (43–1,821) | 0.184 |
| Median AST (U/liter) (range) | 174.5 (39–563) | 118 (56–216) | 87 (25–1,384) | 0.221 |
| Median total bilirubin (mg/dl) (range) | 0.78 (0.4–1.2) | 0.91 (0.6–1.5) | 0.82 (0.2–10) | 0.752 |
| Mean PT (INR) ± SD | 1.03 ± 0.09 | 1.03 ± 0.064 | 1.04 ± 0.09 | 0.991 |
| Mean platelets (×10^3/µl) ± SD | 168.9 ± 68.7 | 174.8 ± 40.3 | 176.6 ± 39.9 | 0.553 |
| Median AFP (ng/ml) (range) | 6.3 (4–114) | 26 (10–44) | 5.9 (2–36) | 0.055 |
| Mean Ishak fibrosis stage ± SD | 2.13 ± 1.25 | 2.75 ± 2.22 | 2.04 ± 1.22 | 0.875 |
| Mean Ishak necroinflammation grading ± SD | 7.63 ± 3.42 | 7.75 ± 0.96 | 5.65 ± 2.41 | 0.101 |
| Median HBV DNA (log_{10} cp/ml) (range) | 6.30 (3.36–7.97) | 7.19 (4.79–8.49) | 7.72 (4.99–9.84) | 0.061 |

* PT, INR, and AFP are as defined for Table 1.

b The Kruskal-Wallis ANOVA test was used for statistical analysis of the three groups.

c Mixed nuclear and cytoplasmic localization.
bution associated with hepatic necroinflammation. However, patients with isolated cytoplasmic HBcAg expression seemed to have lower HBV DNA levels, but the difference did not reach statistical significance. Only a high degree of expression of HBcAg (≥3 /H11001 /H11001 ≥4 /H11001) was associated with high HBV DNA load (Fig. 1B). The distribution and level of HBcAg expression may have different characteristics in HBeAg-negative CHB patients. HBV DNA load is associated with the risk of cirrhosis and HCC (4, 16). Antiviral treatment to reduce the HBV DNA can improve the disease outcome (3). It is well accepted that high HBV DNA levels play an adverse role in liver histological grading. For HBeAg-negative CHB, an HBV DNA load higher than 20,000 IU/ml or 1 × 10^5 cp/ml is a common criterion for safety diagnosis; however, the finding of low HBV DNA load could not exclude the possibility of active hepatic necroinflammation (28). A previous study could not explain why significant

TABLE 5. Factors associated with active liver inflammation in 39 HBeAg-negative CHB patients with low viral load (DNA ≤ 1 × 10^6 cp/ml)

| Factor | Fraction (%) of patients with Ishak inflammation grading ≥7 | p^b |
|--------|-------------------------------------------------------------|-----|
| Age (yr), ≤50 vs >50 | 3/23 (13) vs 4/16 (25) | 0.415 |
| Sex, male vs female | 5/27 (18.5) vs 2/12 (16.7) | 1.0 |
| ALT (U/liter), ≤160 vs >160 | 3/25 (12) vs 4/14 (28.6) | 0.225 |
| AST (U/liter) ≤80 vs >80 | 4/23 (17.4) vs 3/16 (18.8) | 1.0 |
| Total bilirubin (mg/dl), ≤1.6 vs >1.6 | 6/38 (15.8) vs 1/1 (100) | 0.179 |
| PT (INR), ≤1.1 vs >1.1 | 7/36 (19.4) vs 0/3 (0) | 1.0 |
| Platelets, ≤150,000 vs >150,000 | 2/4 (50) vs 5/35 (14.3) | 0.141 |
| AFP (ng/ml), ≤20 vs >20 | 6/33 (18.2) vs 0/3 (0) | 1.0 |
| Intrahepatic HBeAg, negative vs positive | 4/34 (11.8) vs 3/5 (60) | 0.032 |

^a PT, INR, and AFP are as defined for Table 2.
^b Fisher’s exact test was used for statistical analysis.

FIG. 2. Correlation of HBV DNA load with (A) the seropositivity of HBcAg expression and (B) the grading of Ishak necroinflammation. The Kruskal-Wallis ANOVA test was used for statistical analysis among groups. (C) Association of HBV DNA levels with Ishak inflammatory grading (left) and the influence of HBcAg on the Ishak necroinflammation grading in patients with high (middle) or low (right) HBV DNA loads. The Mann-Whitney U test was used for statistical analysis.
necroinflammation existed in HBeAg-negative CHB patients with low HBV viral loads. The current findings show that HBeAg expression is an important factor associated with significant liver necroinflammation in such populations.

Sampling error is inevitable in liver biopsy. However, the finding that patients with HBCAg expression had significantly higher HBV DNA loads and severe hepatic necroinflammation suggested that sampling error could not completely explain the negativity of HBeAg in HBeAg-negative CHB. A previous study suggested that purely cytoplasmic HBeAg expression was more frequent in the presence of the precore 1896 mutation, which may block the translocation of HBeAg (29, 25). A recent study revealed that a basal core promoter (BCP) HBV mutant had lower intrahepatic HBeAg expression in HBeAg-positive CHB (21). In this retrospective study, the serum samples were not available for HBV genotyping and sequencing. Whether HBV genotype and mutations would influence the expression of intrahepatic HBeAg in HBeAg-negative CHB deserves further study in the future. Another limitation of the study is that the status of HBeAg in HBeAg-negative patients with normal ALT levels or low viral loads is still unknown. However, such cases usually represent inactive HBV carriers. Therefore, liver biopsy is not indicated in clinical practice.

In conclusion, the expression of HBeAg is not frequent in HBeAg-negative CHB. Only a high level of HBeAg expression is correlated with high HBV DNA loads. Antiviral treatment might be considered for patients with low levels of viremia but who are positive for intrahepatic HBeAg. The expression of intrahepatic HBeAg is associated with active hepatic necroinflammation, even in patients with low HBV DNA loads.

ACKNOWLEDGMENTS

This work was supported by grants from Taipei Veterans General Hospital (VGH98A-026, V97C1-044, and V98C1-087), Taipei, Taiwan.

REFERENCES

1. Burrell, C. J., E. J. Gowans, and B. P. MARMION. 1985. High levels of cyttoplasmic hepatitis B core antigen as reliable marker of HBV DNA replication. Lancet i:644–455.

2. Carman, W. F., M. R. Jacyna, S. Hadziyannis, P. Karayiannis, M. J. McGarvey, A. Makris, and H. C. Thomas. 1989. Mutation preventing formation of hepatitis B core antigen in patients with chronic hepatitis B infection. Lancet i:358–359.

3. Chen, C. J., H. I. Yang, and U. H. Iloje. 2009. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 49:572–584.

4. Chen, C. J., H. I. Yang, J. Su, C. L. Jen, S. L. You, S. N. Lu, G. T. Huang, and U. H. Iloje. 2006. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:565–73.

5. Chisari, F. V., and C. Ferrari. 1995. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:29–60.

6. Chu, C. M., and Y. F. Liaw. 1992. Immunohistochemical study of intrahepatic expression of hepatitis B core and E antigens in chronic type B hepatitis. J. Clin. Pathol. 45:791–795.

7. Chu, C. M., and Y. F. Liaw. 1987. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology 92:220–225.

8. Chu, C. M., C. T. Yeh, R. N. Chien, I. S. Sheen, and Y. F. Liaw. 1997. The degrees of hepatocyte nuclear but not cytoplasmic expression of hepatitis B core antigen reflect the level of viral replication in chronic hepatitis B virus infection. J. Clin. Microbiol. 35:102–105.

9. Chu, C. M., C. T. Yeh, I. S. Sheen, and Y. F. Liaw. 1995. Subcellular localization of hepatitis B core antigen in relation to hepatocyte regeneration in chronic hepatitis B. Gastroenterology 109:1926–1932.

10. Ganem, D., and H. E. VARMUS. 1987. The molecular biology of the hepatitis B viruses. Annu. Rev. Biochem. 56:651–693.

11. Gowans, E. J., C. J. Burrell, A. R. Jilbert, and B. P. MARMION. 1985. Cyttoplasmic (but not nuclear) hepatitis B virus (HBV) core antigen reflects HBV DNA synthesis at the level of the infected hepatocyte. Intervirology 24:220–225.